UBS Upgrades AstraZeneca PLC - Depositary Receipt
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
AstraZeneca PLC (LON:AZN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £114.82 ($144.52) and traded as high as ...
AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...
AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Shares in drugs giant AstraZeneca (AZN) looked perkier today as it reported a rise in sales and eased investor fears over the ...
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...
AstraZeneca's improving financial position isn't yet fully reflected in its stock price AstraZeneca's revenue was about $13.57 billion in the third quarter of 2024, up 18.1% year-over-year and ...
Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback